RSS feed

Publications by Maren Høland

10 publications found

Original articles

Høland M, Berg KCG, Eilertsen IA, Bjerkehagen B, Kolberg M, Boye K, Lingjærde OC, Guren TK, Mandahl N, van den Berg E, Palmerini E, Smeland S, Picci P, Mertens F, Sveen A, Lothe RA (2023)
Transcriptomic subtyping of malignant peripheral nerve sheath tumours highlights immune signatures, genomic profiles, patient survival and therapeutic targets
EBioMedicine, 97, 104829
DOI 10.1016/j.ebiom.2023.104829, PubMed 37837931

Hoff AM, Kraggerud SM, Alagaratnam S, Berg KCG, Johannessen B, Høland M, Nilsen G, Lingjærde OC, Andrews PW, Lothe RA, Skotheim RI (2020)
Frequent copy number gains of SLC2A3 and ETV1 in testicular embryonal carcinomas
Endocr Relat Cancer, 27 (9), 457-468
DOI 10.1530/ERC-20-0064, PubMed 32580154

Berg KCG, Sveen A, Høland M, Alagaratnam S, Berg M, Danielsen SA, Nesbakken A, Søreide K, Lothe RA (2019)
Gene expression profiles of CMS2-epithelial/canonical colorectal cancers are largely driven by DNA copy number gains
Oncogene, 38 (33), 6109-6122
DOI 10.1038/s41388-019-0868-5, PubMed 31308487

Høland M, Kolberg M, Danielsen SA, Bjerkehagen B, Eilertsen IA, Hektoen M, Mandahl N, van den Berg E, Smeland S, Mertens F, Sundby Hall K, Picci P, Sveen A, Lothe RA (2018)
Inferior survival for patients with malignant peripheral nerve sheath tumors defined by aberrant TP53
Mod Pathol, 31 (11), 1694-1707
DOI 10.1038/s41379-018-0074-y, PubMed 29946184

Kolberg M, Bruun J, Murumägi A, Mpindi JP, Bergsland CH, Høland M, Eilertsen IA, Danielsen SA, Kallioniemi O, Lothe RA (2017)
Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors
Mol Oncol, 11 (9), 1156-1171
DOI 10.1002/1878-0261.12086, PubMed 28556483

Sveen A, Løes IM, Alagaratnam S, Nilsen G, Høland M, Lingjærde OC, Sorbye H, Berg KC, Horn A, Angelsen JH, Knappskog S, Lønning PE, Lothe RA (2016)
Intra-patient Inter-metastatic Genetic Heterogeneity in Colorectal Cancer as a Key Determinant of Survival after Curative Liver Resection
PLoS Genet, 12 (7), e1006225
DOI 10.1371/journal.pgen.1006225, PubMed 27472274

Kolberg M, Høland M, Lind GE, Ågesen TH, Skotheim RI, Hall KS, Mandahl N, Smeland S, Mertens F, Davidson B, Lothe RA (2015)
Protein expression of BIRC5, TK1, and TOP2A in malignant peripheral nerve sheath tumours--A prognostic test after surgical resection
Mol Oncol, 9 (6), 1129-39
DOI 10.1016/j.molonc.2015.02.005, PubMed 25769404

Danielsen SA, Lind GE, Kolberg M, Høland M, Bjerkehagen B, Sundby Hall K, van den Berg E, Mertens F, Smeland S, Picci P, Lothe RA (2014)
Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis
Neuro Oncol, 17 (1), 63-9
DOI 10.1093/neuonc/nou140, PubMed 25038505

Review articles

Kolberg M, Høland M, Agesen TH, Brekke HR, Liestøl K, Hall KS, Mertens F, Picci P, Smeland S, Lothe RA (2012)
Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1
Neuro Oncol, 15 (2), 135-47
DOI 10.1093/neuonc/nos287, PubMed 23161774

Theses

Høland M (2010)
Prognostic value of protein markers in malignant peripheral nerve sheath tumours
M. Høland, Oslo, XII, 146 s.
BIBSYS 101476809